{"id":15235,"date":"2025-09-11T04:28:07","date_gmt":"2025-09-11T04:28:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/15235\/"},"modified":"2025-09-11T04:28:07","modified_gmt":"2025-09-11T04:28:07","slug":"ai-tools-are-spreading-medical-scams-online","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/15235\/","title":{"rendered":"AI Tools Are Spreading Medical Scams Online"},"content":{"rendered":"<p>In this week\u2019s edition of InnovationRx, we look at AI medical scams, using machine learning to derive drugs from nature, Summit Therapeutics\u2019 miss, and more. To get it in your inbox, <a href=\"https:\/\/www.forbes.com\/newsletter\/innovationrx\/#3ffe45a750f4\" target=\"_self\" class=\"color-link\" title=\"https:\/\/www.forbes.com\/newsletter\/innovationrx\/#3ffe45a750f4\" data-ga-track=\"InternalLink:https:\/\/www.forbes.com\/newsletter\/innovationrx\/#3ffe45a750f4\" aria-label=\"subscribe here\" rel=\"nofollow noopener\">subscribe here<\/a>.<\/p>\n<p>Beware of online medical scams. Fake AI doctors\u2014some stealing real doctors\u2019 faces and voices\u2014are hawking dubious healthcare products online.<\/p>\n<p>Last week, the <a href=\"https:\/\/www.nytimes.com\/2025\/09\/05\/technology\/ai-doctor-scams.html\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.nytimes.com\/2025\/09\/05\/technology\/ai-doctor-scams.html\" data-ga-track=\"ExternalLink:https:\/\/www.nytimes.com\/2025\/09\/05\/technology\/ai-doctor-scams.html\" aria-label=\"New York Times\">New York Times<\/a> delved into the ways scammers are using increasingly prevalent AI tools to create likenesses of real medical doctors to promote \u201cliquid pearls\u201d for weight loss and high-dose (potentially dangerous) supplements. An <a href=\"https:\/\/url.us.m.mimecastprotect.com\/s\/HDqBCERKo3tXqNVmiZtjt7cT1E?domain=cbsnews.com\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/url.us.m.mimecastprotect.com\/s\/HDqBCERKo3tXqNVmiZtjt7cT1E?domain=cbsnews.com\/\" data-ga-track=\"ExternalLink:https:\/\/url.us.m.mimecastprotect.com\/s\/HDqBCERKo3tXqNVmiZtjt7cT1E?domain=cbsnews.com\/\" aria-label=\"earlier CBS News investigation\">earlier CBS News investigation<\/a> found dozens of accounts and more than 100 videos in which fictitious doctors\u2014some using real ones\u2019 identities\u2014gave medical advice or sold dubious products. Digital risk protection company BrandShield said its research had discovered a global scam network selling fake GLP-1 weight loss drugs and other treatments by impersonating both real doctors and healthcare groups such as the American Diabetes Association and the Mayo Clinic.<\/p>\n<p>While the FDA and other government agencies, as well as advocacy groups, have warned repeatedly about counterfeit and fraudulent treatments and supplements being sold online, it\u2019s become an endless game of whack-a-mole. Promotions of dubious health products online were a problem long before AI. But because AI scammers need only a LinkedIn profile or voice snippet to generate convincing fake content, the newer scams have become even more difficult to stop.<\/p>\n<p>Enveda Raises $150 Million To Use AI To Develop Drugs From Nature<\/p>\n<p>Enveda CEO Viswa Colluru<\/p>\n<p>Enveda<\/p>\n<p>The natural world is the source of many medicines we take for granted today: aspirin comes from willow bark, penicillin from mold and statins from fungus. But finding potential new drugs from the natural world can be a long and expensive process.<\/p>\n<p>Boulder, Colo.-based Enveda aims to speed this process up with AI. Its software scours data from thousands of different plants, looking for chemicals that might be useful for new treatments, which the company then refines and tests. The six-year-old startup currently has one drug, a treatment for atopic dermatitis, in early clinical trials.<\/p>\n<p>Last week, Enveda <a href=\"https:\/\/www.businesswire.com\/news\/home\/20250904184822\/en\/Enveda-Raises-%24150M-Series-D-Funding-to-Reach-Unicorn-Status-Enrolls-First-Patient-in-Lead-Program-and-Adds-Mikael-Dolsten-to-Board-of-Directors\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.businesswire.com\/news\/home\/20250904184822\/en\/Enveda-Raises-%24150M-Series-D-Funding-to-Reach-Unicorn-Status-Enrolls-First-Patient-in-Lead-Program-and-Adds-Mikael-Dolsten-to-Board-of-Directors\" data-ga-track=\"ExternalLink:https:\/\/www.businesswire.com\/news\/home\/20250904184822\/en\/Enveda-Raises-%24150M-Series-D-Funding-to-Reach-Unicorn-Status-Enrolls-First-Patient-in-Lead-Program-and-Adds-Mikael-Dolsten-to-Board-of-Directors\" aria-label=\"raised $150 million\">raised $150 million<\/a>, bringing its total funding to $517 million, at a <a href=\"https:\/\/www.axios.com\/pro\/biotech-deals\/2025\/09\/04\/enveda-raises-150m-unicorn-status\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.axios.com\/pro\/biotech-deals\/2025\/09\/04\/enveda-raises-150m-unicorn-status\" data-ga-track=\"ExternalLink:https:\/\/www.axios.com\/pro\/biotech-deals\/2025\/09\/04\/enveda-raises-150m-unicorn-status\" aria-label=\"valuation of more than $1 billion.\">valuation of more than $1 billion.<\/a> The round was led by Premji Invest, the family office of <a href=\"https:\/\/www.forbes.com\/profile\/azim-premji\/\" target=\"_self\" class=\"color-link\" title=\"https:\/\/www.forbes.com\/profile\/azim-premji\/\" data-ga-track=\"InternalLink:https:\/\/www.forbes.com\/profile\/azim-premji\/\" aria-label=\"Indian billionaire Azim Premji, founder of Wipro\" rel=\"nofollow noopener\">Indian billionaire Azim Premji, founder of Wipro<\/a>.<\/p>\n<p>With the new capital, the company plans to bring several more drugs into clinical trials, tackling diseases that include asthma, inflammatory bowel disease and obesity. The startup also announced that Mikael Dolsten, Pfizer\u2019s former chief scientific officer, joined the company\u2019s board.<\/p>\n<p>BIOTECH AND PHARMA<\/p>\n<p>Summit Therapeutics <a href=\"https:\/\/www.statnews.com\/2025\/09\/07\/summit-therapeutics-lung-cancer-ivonescimab\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.statnews.com\/2025\/09\/07\/summit-therapeutics-lung-cancer-ivonescimab\/\" data-ga-track=\"ExternalLink:https:\/\/www.statnews.com\/2025\/09\/07\/summit-therapeutics-lung-cancer-ivonescimab\/\" aria-label=\"lung cancer drug doesn\u2019t seem to work as well in patients in North America and Europe\">lung cancer drug doesn\u2019t seem to work as well in patients in North America and Europe<\/a> as it does in China. In a study update reported on Sunday, the biotech said that patients treated with its drug, ivonescimab, and chemotherapy saw 33% reduced risk of tumor progression versus chemotherapy and a placebo, an outcome that failed to reach statistical significance. That compares with a 45% reduction for participants in China, and is a tough result for Summit, which garnered attention last year when it beat Merck\u2019s blockbuster cancer drug Keytruda in an earlier study. Its shares fell 25% on the results on Monday. Forbes previously profiled Summit\u2019s <a href=\"https:\/\/www.forbes.com\/sites\/kerryadolan\/2025\/06\/03\/the-unlikely-path-from-iranian-revolution-to-billionaire-biotech-ceo\/\" target=\"_self\" class=\"color-link\" title=\"https:\/\/www.forbes.com\/sites\/kerryadolan\/2025\/06\/03\/the-unlikely-path-from-iranian-revolution-to-billionaire-biotech-ceo\/\" data-ga-track=\"InternalLink:https:\/\/www.forbes.com\/sites\/kerryadolan\/2025\/06\/03\/the-unlikely-path-from-iranian-revolution-to-billionaire-biotech-ceo\/\" aria-label=\"co-CEO Maky Zanganeh.\" rel=\"nofollow noopener\">co-CEO Maky Zanganeh.<\/a><\/p>\n<p>Plus: Novartis agreed to <a href=\"https:\/\/endpoints.news\/novartis-to-spend-1-4b-on-tourmaline-bio-gaining-new-heart-drug\/?u=3008a15c-678a-4002-8b08-23a5a8ee5eb8&amp;s=email&amp;c=ead60ced-0cd401da-9810245b&amp;utm_medium=email&amp;utm_campaign=991%20-%20Novartis%20to%20buy%20Tourmaline%20Bio%20Lilly%20welcomes%20biotechs%20to%20use%20its%20AI%20models%20Basic&amp;utm_content=991%20-%20Novartis%20to%20buy%20Tourmaline%20Bio%20Lilly%20welcomes%20biotechs%20to%20use%20its%20AI%20models%20Basic+CID_ed1baa00a8073e6654e20e933bd9d518&amp;utm_source=ENDPOINTS%20emails&amp;utm_term=Novartis%20to%20spend%2014B%20on%20Tourmaline%20Bio%20gaining%20new%20heart%20drug\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/endpoints.news\/novartis-to-spend-1-4b-on-tourmaline-bio-gaining-new-heart-drug\/?u=3008a15c-678a-4002-8b08-23a5a8ee5eb8&amp;s=email&amp;c=ead60ced-0cd401da-9810245b&amp;utm_medium=email&amp;utm_campaign=991%20-%20Novartis%20to%20buy%20Tourmaline%20Bio%20Lilly%20welcomes%20biotechs%20to%20use%20its%20AI%20models%20Basic&amp;utm_content=991%20-%20Novartis%20to%20buy%20Tourmaline%20Bio%20Lilly%20welcomes%20biotechs%20to%20use%20its%20AI%20models%20Basic+CID_ed1baa00a8073e6654e20e933bd9d518&amp;utm_source=ENDPOINTS%20emails&amp;utm_term=Novartis%20to%20spend%2014B%20on%20Tourmaline%20Bio%20gaining%20new%20heart%20drug\" data-ga-track=\"ExternalLink:https:\/\/endpoints.news\/novartis-to-spend-1-4b-on-tourmaline-bio-gaining-new-heart-drug\/?u=3008a15c-678a-4002-8b08-23a5a8ee5eb8&amp;s=email&amp;c=ead60ced-0cd401da-9810245b&amp;utm_medium=email&amp;utm_campaign=991%20-%20Novartis%20to%20buy%20Tourmaline%20Bio%20Lilly%20welcomes%20biotechs%20to%20use%20its%20AI%20models%20Basic&amp;utm_content=991%20-%20Novartis%20to%20buy%20Tourmaline%20Bio%20Lilly%20welcomes%20biotechs%20to%20use%20its%20AI%20models%20Basic+CID_ed1baa00a8073e6654e20e933bd9d518&amp;utm_source=ENDPOINTS%20emails&amp;utm_term=Novartis%20to%20spend%2014B%20on%20Tourmaline%20Bio%20gaining%20new%20heart%20drug\" aria-label=\"buy Tourmaline Bio for $1.4 billion,\">buy Tourmaline Bio for $1.4 billion,<\/a> a premium of nearly 60% the biotech\u2019s closing price on Monday, in order to gain a new heart drug and revitalize its cardiovascular pipeline. The patent on the company\u2019s blockbuster drug for heart failure, Entresto, is <a href=\"https:\/\/www.reuters.com\/legal\/litigation\/novartis-loses-bid-block-us-entresto-generic-through-2026-2025-07-11\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.reuters.com\/legal\/litigation\/novartis-loses-bid-block-us-entresto-generic-through-2026-2025-07-11\/\" data-ga-track=\"ExternalLink:https:\/\/www.reuters.com\/legal\/litigation\/novartis-loses-bid-block-us-entresto-generic-through-2026-2025-07-11\/\" aria-label=\"set to expire soon.\">set to expire soon.<\/a><\/p>\n<p>DIGITAL HEALTH AND AI<\/p>\n<p>Pharmaceutical giant Eli Lilly <a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-launches-tunelab-platform-give-biotechnology-companies\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-launches-tunelab-platform-give-biotechnology-companies\" data-ga-track=\"ExternalLink:https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-launches-tunelab-platform-give-biotechnology-companies\" aria-label=\"launched\">launched<\/a> Tunelab this week, an AI platform for drug discovery trained on the company\u2019s own data, which will be offered to select biotechs in exchange for training data. The company said that Tunelab will be hosted by a third-party to prevent Lilly from having direct access to any of its partners\u2019 proprietary information. Circle Pharma, <a href=\"https:\/\/www.businesswire.com\/news\/home\/20250908930374\/en\/Circle-Pharma-Announces-Agreement-with-Lilly-to-Further-Enhance-AIML-Capabilities-and-Accelerate-Development-of-New-Oral-Macrocycle-Therapies\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.businesswire.com\/news\/home\/20250908930374\/en\/Circle-Pharma-Announces-Agreement-with-Lilly-to-Further-Enhance-AIML-Capabilities-and-Accelerate-Development-of-New-Oral-Macrocycle-Therapies\" data-ga-track=\"ExternalLink:https:\/\/www.businesswire.com\/news\/home\/20250908930374\/en\/Circle-Pharma-Announces-Agreement-with-Lilly-to-Further-Enhance-AIML-Capabilities-and-Accelerate-Development-of-New-Oral-Macrocycle-Therapies\" aria-label=\"announced\">announced<\/a> Tuesday that it would use the platform in conjunction with its own software to discover potential cancer treatments using currently undruggable targets. Insitro, meanwhile, will partner with Lilly to build new AI models for the <a href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/lilly-launches-ai-powered-platform-accelerate-drug-discovery-2025-09-09\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/lilly-launches-ai-powered-platform-accelerate-drug-discovery-2025-09-09\/\" data-ga-track=\"ExternalLink:https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/lilly-launches-ai-powered-platform-accelerate-drug-discovery-2025-09-09\/\" aria-label=\"discovery of small molecule therapies\">discovery of small molecule therapies<\/a>.<\/p>\n<p>MEDTECH<\/p>\n<p>The FDA approved <a href=\"https:\/\/egenesisbio.com\/press-releases\/egenesis-announces-ind-clearance-for-egen-2784-in-kidney-transplant-and-landmark-patient-updates-in-ongoing-expanded-access-study\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/egenesisbio.com\/press-releases\/egenesis-announces-ind-clearance-for-egen-2784-in-kidney-transplant-and-landmark-patient-updates-in-ongoing-expanded-access-study\/\" data-ga-track=\"ExternalLink:https:\/\/egenesisbio.com\/press-releases\/egenesis-announces-ind-clearance-for-egen-2784-in-kidney-transplant-and-landmark-patient-updates-in-ongoing-expanded-access-study\/\" aria-label=\"a clinical trial\">a clinical trial<\/a> of genetically modified pig kidneys in human transplant cases for late-stage kidney disease. The study, by xenotransplant startup eGenesis, will test the safety, tolerability and efficacy of the kidney at 24 weeks after being transplanted into older patients who are on dialysis, are facing end-stage kidney disease or are on the transplant list. The Cambridge, Mass.-based startup\u2019s kidneys have been transplanted into three patients so far, one of whom remains healthy seven months post-operation. Forbes <a href=\"https:\/\/www.forbes.com\/sites\/alexknapp\/2024\/03\/27\/the-startup-behind-the-first-pig-human-kidney-transplant-is-targeting-hearts-and-livers-next\/\" target=\"_self\" class=\"color-link\" title=\"https:\/\/www.forbes.com\/sites\/alexknapp\/2024\/03\/27\/the-startup-behind-the-first-pig-human-kidney-transplant-is-targeting-hearts-and-livers-next\/\" data-ga-track=\"InternalLink:https:\/\/www.forbes.com\/sites\/alexknapp\/2024\/03\/27\/the-startup-behind-the-first-pig-human-kidney-transplant-is-targeting-hearts-and-livers-next\/\" aria-label=\"profiled\" rel=\"nofollow noopener\">profiled<\/a> the company and its technology last year.<\/p>\n<p>PUBLIC HEALTH AND HOSPITALS<\/p>\n<p>Employees should expect <a href=\"https:\/\/www.nytimes.com\/2025\/09\/04\/health\/health-care-costs-employers-workers.html\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.nytimes.com\/2025\/09\/04\/health\/health-care-costs-employers-workers.html\" data-ga-track=\"ExternalLink:https:\/\/www.nytimes.com\/2025\/09\/04\/health\/health-care-costs-employers-workers.html\" aria-label=\"higher health care costs next year,\">higher health care costs next year,<\/a> including increases in premiums, bigger deductibles and higher copays, according to a large survey of employers by benefits consultant Mercer. Employers\u2019 total health benefit cost per employee is forecast to rise 6.5% on average in 2026\u2013the <a href=\"https:\/\/www.mercer.com\/en-us\/insights\/us-health-news\/employers-prepare-for-the-highest-health-benefit-cost-increase-in-15-years\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.mercer.com\/en-us\/insights\/us-health-news\/employers-prepare-for-the-highest-health-benefit-cost-increase-in-15-years\/\" data-ga-track=\"ExternalLink:https:\/\/www.mercer.com\/en-us\/insights\/us-health-news\/employers-prepare-for-the-highest-health-benefit-cost-increase-in-15-years\/\" aria-label=\"largest increase in 15 years\">largest increase in 15 years<\/a>\u2013while the majority of employers surveyed said they planned to cut their own costs by raising deductibles or reducing benefits. Without those cuts, the per-employee cost would go up nearly 9%, according to the survey. The projected increase comes as consumers are already feeling squeezed by higher costs.<\/p>\n<p>Plus: President Trump <a href=\"https:\/\/www.forbes.com\/sites\/antoniopequenoiv\/2025\/09\/09\/trump-signs-order-targeting-drug-ads-on-tv-but-stops-short-of-ban-rfk-jr-proposed\/\" target=\"_self\" class=\"color-link\" title=\"https:\/\/www.forbes.com\/sites\/antoniopequenoiv\/2025\/09\/09\/trump-signs-order-targeting-drug-ads-on-tv-but-stops-short-of-ban-rfk-jr-proposed\/\" data-ga-track=\"InternalLink:https:\/\/www.forbes.com\/sites\/antoniopequenoiv\/2025\/09\/09\/trump-signs-order-targeting-drug-ads-on-tv-but-stops-short-of-ban-rfk-jr-proposed\/\" aria-label=\"signed an executive order\" rel=\"nofollow noopener\">signed an executive order<\/a> tightening restrictions on drug ads. The FDA said it will send thousands of letters to pharmaceutical companies, including 100 cease and desists, to enforce the new rules.<\/p>\n<p>WHAT WE\u2019RE READING<\/p>\n<p>BioZorb breast implants, used to help patients with cancer, were supposed to dissolve. <a href=\"https:\/\/www.bloomberg.com\/features\/2025-biozorb-cancer-implant-recall\/?cmpid=BBD090525_prognosis&amp;utm_medium=email&amp;utm_source=newsletter&amp;utm_term=250905&amp;utm_campaign=prognosis\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.bloomberg.com\/features\/2025-biozorb-cancer-implant-recall\/?cmpid=BBD090525_prognosis&amp;utm_medium=email&amp;utm_source=newsletter&amp;utm_term=250905&amp;utm_campaign=prognosis\" data-ga-track=\"ExternalLink:https:\/\/www.bloomberg.com\/features\/2025-biozorb-cancer-implant-recall\/?cmpid=BBD090525_prognosis&amp;utm_medium=email&amp;utm_source=newsletter&amp;utm_term=250905&amp;utm_campaign=prognosis\" aria-label=\"When they didn\u2019t\">When they didn\u2019t<\/a>, patients were left with searing pain, dying breast tissue and infections. The implants\u2019 maker kept those complaints from the public.<\/p>\n<p>As HHS Secretary Robert F. Kennedy Jr. sows distrust of vaccines and dismantles the federal infrastructure for them, states are making up <a href=\"https:\/\/www.theatlantic.com\/health\/archive\/2025\/09\/vaccines-rfk-states-covid\/684121\/?utm_medium=offsite&amp;utm_source=google&amp;utm_campaign=newsstand-health\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.theatlantic.com\/health\/archive\/2025\/09\/vaccines-rfk-states-covid\/684121\/?utm_medium=offsite&amp;utm_source=google&amp;utm_campaign=newsstand-health\" data-ga-track=\"ExternalLink:https:\/\/www.theatlantic.com\/health\/archive\/2025\/09\/vaccines-rfk-states-covid\/684121\/?utm_medium=offsite&amp;utm_source=google&amp;utm_campaign=newsstand-health\" aria-label=\"their own rules\">their own rules<\/a>.<\/p>\n<p>Two former top NIH officials <a href=\"https:\/\/www.statnews.com\/2025\/09\/04\/nih-whistleblower-complaints-research-grants-flu-vaccine-jeanne-marrazzo\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.statnews.com\/2025\/09\/04\/nih-whistleblower-complaints-research-grants-flu-vaccine-jeanne-marrazzo\/\" data-ga-track=\"ExternalLink:https:\/\/www.statnews.com\/2025\/09\/04\/nih-whistleblower-complaints-research-grants-flu-vaccine-jeanne-marrazzo\/\" aria-label=\"filed whistleblower complaints\">filed whistleblower complaints<\/a> alleging they were illegally fired for objecting to grant cancellations and political interference in the agency\u2019s decisionmaking.<\/p>\n<p>Covid <a href=\"https:\/\/www.sfchronicle.com\/health\/article\/california-covid-hospitalizations-vaccines-21037066.php\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.sfchronicle.com\/health\/article\/california-covid-hospitalizations-vaccines-21037066.php\" data-ga-track=\"ExternalLink:https:\/\/www.sfchronicle.com\/health\/article\/california-covid-hospitalizations-vaccines-21037066.php\" aria-label=\"hospitalizations in California have double\">hospitalizations in California have double<\/a>d as vaccine access in the state tightened.<\/p>\n<p>Florida\u2019s surgeon general <a href=\"https:\/\/www.cnn.com\/2025\/09\/09\/health\/floridas-surgeon-general-calculate-costs-vaccine-mandates\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.cnn.com\/2025\/09\/09\/health\/floridas-surgeon-general-calculate-costs-vaccine-mandates\" data-ga-track=\"ExternalLink:https:\/\/www.cnn.com\/2025\/09\/09\/health\/floridas-surgeon-general-calculate-costs-vaccine-mandates\" aria-label=\"told CNN\">told CNN<\/a> that he had not weighed the cost of eliminating vaccine mandates in the state, which scientists estimate could lead to hundreds of thousands of cases of measles and other preventable infections.<\/p>\n<p>A <a href=\"https:\/\/www.epicresearch.org\/articles\/two-years-after-stopping-glp-1s-most-patients-sustain-at-least-some-weight-loss\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.epicresearch.org\/articles\/two-years-after-stopping-glp-1s-most-patients-sustain-at-least-some-weight-loss\" data-ga-track=\"ExternalLink:https:\/\/www.epicresearch.org\/articles\/two-years-after-stopping-glp-1s-most-patients-sustain-at-least-some-weight-loss\" aria-label=\"new study\">new study<\/a> of patients who stopped GLP-1 drugs found that most sustained at least some weight loss after two years and more than 50% either stayed at their lower weight or lost more.<\/p>\n<p>Novo Nordisk, the maker of Ozempic and Wegovy, is <a href=\"https:\/\/www.reuters.com\/business\/novo-nordisk-slashes-9000-jobs-slim-down-fierce-weight-loss-drug-battle-2025-09-10\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.reuters.com\/business\/novo-nordisk-slashes-9000-jobs-slim-down-fierce-weight-loss-drug-battle-2025-09-10\/\" data-ga-track=\"ExternalLink:https:\/\/www.reuters.com\/business\/novo-nordisk-slashes-9000-jobs-slim-down-fierce-weight-loss-drug-battle-2025-09-10\/\" aria-label=\"cutting 9,000 jobs\">cutting 9,000 jobs<\/a> as its growth\u2013and stock price\u2013have slumped.<\/p>\n<p>Robert F. Kennedy, Jr. is considering adding <a href=\"https:\/\/www.washingtonpost.com\/health\/2025\/09\/08\/rfk-jr-new-vaccine-advisers\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.washingtonpost.com\/health\/2025\/09\/08\/rfk-jr-new-vaccine-advisers\/\" data-ga-track=\"ExternalLink:https:\/\/www.washingtonpost.com\/health\/2025\/09\/08\/rfk-jr-new-vaccine-advisers\/\" aria-label=\"seven more people\">seven more people<\/a> to the CDC\u2019s vaccine advisory committee, several of whom are highly critical of COVID vaccines\u2013including two who previously called for the FDA to revoke their approval.<\/p>\n<p>HHS is <a href=\"https:\/\/www.404media.co\/hhs-asks-all-employees-to-start-using-chatgpt\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\" class=\"color-link\" title=\"https:\/\/www.404media.co\/hhs-asks-all-employees-to-start-using-chatgpt\/\" data-ga-track=\"ExternalLink:https:\/\/www.404media.co\/hhs-asks-all-employees-to-start-using-chatgpt\/\" aria-label=\"rolling out ChatGPT\">rolling out ChatGPT<\/a> to its employees and encouraging its use. Note: when Forbes prompted it with the question \u201cAre COVID vaccines effective?\u201d ChatGPT replied \u201cShort answer: yes\u2013especially for preventing severe illness, hospitalization, and death.\u201d<\/p>\n<p>MORE FROM FORBES <a class=\"embed-base color-body color-body-border link-embed embed-83\" href=\"https:\/\/www.forbes.com\/sites\/justinbirnbaum\/2025\/09\/09\/americas-richest-sports-team-owners-2025\/\" target=\"_blank\" aria-label=\"America\u2019s Richest Sports Team Owners 2025\" data-ga-track=\"forbesEmbedly:https:\/\/www.forbes.com\/sites\/justinbirnbaum\/2025\/09\/09\/americas-richest-sports-team-owners-2025\/\" rel=\"nofollow noopener\">ForbesAmerica\u2019s Richest Sports Team Owners 2025By Justin Birnbaum<\/a><a class=\"embed-base color-body color-body-border link-embed embed-89\" href=\"https:\/\/www.forbes.com\/sites\/danalexander\/2025\/09\/09\/presidency-boosts-trumps-net-worth-by-3-billion-in-a-year\/\" target=\"_blank\" aria-label=\"Presidency Boosts Trump\u2019s Net Worth By $3 Billion In A Year\" data-ga-track=\"forbesEmbedly:https:\/\/www.forbes.com\/sites\/danalexander\/2025\/09\/09\/presidency-boosts-trumps-net-worth-by-3-billion-in-a-year\/\" rel=\"nofollow noopener\">ForbesPresidency Boosts Trump\u2019s Net Worth By $3 Billion In A YearBy Dan Alexander<\/a><a class=\"embed-base color-body color-body-border link-embed embed-91\" href=\"https:\/\/www.forbes.com\/sites\/chasewithorn\/2025\/09\/09\/the-2025-forbes-400-list-of-wealthiest-americans-facts-and-figures\/\" target=\"_blank\" aria-label=\"The 2025 Forbes 400 List Of Wealthiest Americans: Facts And Figures\" data-ga-track=\"forbesEmbedly:https:\/\/www.forbes.com\/sites\/chasewithorn\/2025\/09\/09\/the-2025-forbes-400-list-of-wealthiest-americans-facts-and-figures\/\" rel=\"nofollow noopener\">ForbesThe 2025 Forbes 400 List Of Wealthiest Americans: Facts And FiguresBy Chase Peterson-Withorn<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"In this week\u2019s edition of InnovationRx, we look at AI medical scams, using machine learning to derive drugs&hellip;\n","protected":false},"author":2,"featured_media":15236,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[17463,17457,2534,17459,17458,134,527,17456,111,139,17461,69,17460,17462,3059],"class_list":{"0":"post-15235","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-ai-drug-discovery","9":"tag-ai-scams","10":"tag-cancer","11":"tag-enveda","12":"tag-fake-doctors","13":"tag-health","14":"tag-healthcare","15":"tag-medical-scams","16":"tag-new-zealand","17":"tag-newzealand","18":"tag-novartis","19":"tag-nz","20":"tag-summit-therapeutics","21":"tag-tourmaline-bio","22":"tag-vaccines"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/15235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=15235"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/15235\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/15236"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=15235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=15235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=15235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}